Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase)
- 1 March 1994
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 73 (8) , 544-549
- https://doi.org/10.1016/0002-9149(94)90330-1
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapyThe American Journal of Cardiology, 1993
- Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgGHeart, 1992
- Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarctionThe Lancet, 1990
- Antistreptokinase titres after intravenous streptokinaseThe Lancet, 1990
- Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flowThe American Journal of Cardiology, 1989
- Improved survival up to four years after early coronary thrombolysisThe American Journal of Cardiology, 1988
- Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosisThe American Journal of Cardiology, 1986
- The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Semi-automatic method for routine evaluation of fibrinolytic componentsJournal of Clinical Pathology, 1968